Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2023-05-18 00:00:00 ET · period of report 2023-05-16 · accession 0001562180-23-004254 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-18 | 2023-05-16 | AKBA | Burke Steven Keith | SVP, Chief Medical Off | S - Sale | $1.07 | -63.6K | 530.5K | -11% | -$68.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-16 | S | D | 63,567 | $1.07 | 530,487 | D | — | — | (F1) This sale was made automatically by the Issuer pursuant to the Issuer's previously adopted "sell-to-cover" policy to cover tax withholding obligations in connection with the vesting and settlement of 100% of the reporting person's restricted stock units granted on May 12, 2022. |